Hence then, the article about astellas announces zolbetuximab meets primary endpoint in phase 3 glow trial as first line treatment in claudin 18 2 positive her2 negative locally advanced unresectable or metastatic gastric and gastroesophageal junction gej cancers was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers )
Also on site :
- Glynis Johns Earned a Supporting Actress Oscar Nomination for This 1960 Outback Drama, Years Before Her Mary Poppins Fame
- Theme Song for 1970 Robert Altman Film, Ranked Among ‘Best Comedy Movies of All Time,’ Was Written by a 14-Year-Old
- Scarlett Johansson Reunites With Adam Driver and Miles Teller on the Red Carpet After Missing Their Cannes Premiere